Glaukos Corporation (FRA:6GJ)

Market Cap	5.57B
Revenue (ttm)	400.43M
Net Income (ttm)	-74.67M
Shares Out	n/a
EPS (ttm)	-1.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	96.00
Previous Close	95.00
Day's Range	96.00 - 96.00
52-Week Range	63.50 - 152.00
Beta	n/a
RSI	65.97
Earnings Date	Feb 26, 2026

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1998
• Employees: 995
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6GJ

Financial Performance

In 2024, Glaukos's revenue was $383.48 million, an increase of 21.85% compared to the previous year's $314.71 million. Losses were -$146.37 million, 8.70% more than in 2023.

Financial numbers in USD